γ-Linked Dipeptide Analogues of 2-Desamino-2-Methyl-N10-Propargyl-5,8-Dideazafolate as Antitumour Agents

  • A. L. Jackman
  • G. M. F. Bisset
  • D. I. Jodrell
  • W. Gibson
  • R. Kimbell
  • V. Bavetsias
  • A. H. Calvert
  • K. R. Harrap
  • T. C. Stephens
  • M. N. Smith
  • F. T. Boyle
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 338)

Abstract

Quinazoline analogues of folic acid have been developed successfully as thymidylate synthase (TS) inhibitors which possess clinical activity. CB3717 (N10-propargyl-5,8-dideazafolic acid), the first of these agents to receive clinical study, was withdrawn because of nephrotoxicity1. The more water-soluble (and consequently nonnephrotoxic) analogue (ICI D1694) is currently in Phase II clinical study worldwide. ICI D1694 is more potent as an in vitro and in vivo antitumour agent than CB3717 because of its cellular pharmacology2,3. ICI D1694 is actively transported into cells via the reduced-folate/MTX cell membrane carrier (RFC) where it is immediately polyglutamated by the enzyme, folylpolyglutamate synthetase (FPGS). CE3717 either uses this carrier poorly or not at all and therefore enters cells slowly. This, together with poorer substrate activity for FPGS, results in relatively slow formation of polyglutamates. Polyglutamation of quinazoline TS inhibitors has three important consequences: it allows accumulation of drug inside the cell, substantially reduces drug efflux and, because polyglutamates are more potent TS inhibitors than the parent drug, results in improved TS inhibition.

Keywords

Hydrolysis HPLC Lymphoma Benzene Amide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. S.J. Clarke, A.L. Jackman and I.R. Judson.In: “Novel approaches to selective treatment of human solid tumours:laboratory and clinicalcorrelations”. (Y. Rustum. Ed.) Plenum Press, in press.Google Scholar
  2. 2.
    A.L. Jackman, G.A. Taylor, W. Gibson, R. Kimbell,M. Brown, A.H. Calvert, I.R. Judson and L.R. Hughes. Cancer Res. 51: 5529–5586, 1991.Google Scholar
  3. A.L. Jackman, W. Gibson, M. Brown, R. Kimbell andF.T. Boyle. In: “Novel approaches to selective treatment of human tumours: laboratory andclinical correlation”. (Y. Rustum. Ed.) Plenum Press, in press.Google Scholar
  4. 4.
    F.M. Sirotnak, and J.I. DeGraw. In: FolateAntagonists as Therapeutic Agents. Vol.2. (F.M. Sirotnak et al. eds.) Academic Press Inc. pp 43–95, 1984.Google Scholar
  5. 5.
    A.L. Jackman, D.R. Newell, W. Gibson, D.I.Jodrell, G.A. Taylor, J.A. Bishop, L.R. Hughes and A.H. Calvert. Biochem. Pharmacol. 42:1885–1895, 1991.PubMedCrossRefGoogle Scholar
  6. 6.
    A.J. Barker, F.T. Boyle, A.L. Jackman, A.H.Calvert and S.J. Pegg. Proc. Amer. Assoc. Cancer Res. 32: 327, 1991.Google Scholar
  7. 7.
    A.L. Jackman, L.R. Kelland, M. Brown, W. Gibson,R. Kimbell, W. Aherne and I.R. Judson. Proc. Amer. Assoc. Cancer Res. 33: 406, 1992.Google Scholar
  8. 8.
    J.J. McGuire, and J.K. Coward. In: Folates andPterins, Vol.1 (R. Blakley and S.J. Benkovic, eds.) J. Wiley and Sons Inc. pp 135–190, 1984Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • A. L. Jackman
    • 1
  • G. M. F. Bisset
    • 1
  • D. I. Jodrell
    • 1
  • W. Gibson
    • 1
  • R. Kimbell
    • 1
  • V. Bavetsias
    • 1
  • A. H. Calvert
    • 1
  • K. R. Harrap
    • 1
  • T. C. Stephens
    • 2
  • M. N. Smith
    • 2
  • F. T. Boyle
    • 2
  1. 1.Drug Development SectionThe Institute of Cancer ResearchSutton, SurreyUK
  2. 2.ZENECA Pharmaceuticals (ICI)Macclesfield, CheshireUK

Personalised recommendations